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Pathophysiology of Heart Failure
Tori Morrow RN, BSN
Otterbein University, Westervill e, Ohio
Introduction

Underlying Pathophysiology

• As a nurs e in the Emergency Department at Mount
Carmel W es t, many patients come in exhibiting s igns
and s ymptoms of heart failure. N ot every patient

As s tated previous ly, the dis eas e proces s of heart failure can
be caus ed by multiple factors . There are three contributors to
heart contractibility, thes e include preload, contractility, and

dis plays the s ame s ymptoms and not all patients are
on the s ame treatment regimen. It is beneficial for
nurs es taking care of thes e patients to be
knowledgeable on the dis eas e proces s and what
s ymptoms patients can experience.
• Heart failure can be defined as the inability of the
heart to pump effectively enough to meet metabolic
demands of the body’s tis s ues (Lodge & Yous ef, 2016,
p. S12). This could be caus ed by damage to cardiac
tis s ue or as a res ult of dis eas e proces s (Cas ey, 2013, p.
20). Many patients have multiple medical conditions
that can contribute to heart failure. As a res ult,
compens atory mechanis ms may be initiated to
counteract the s ide effects of the dis eas e caus ing
s ys temic changes .

afterload, which all impact s troke volume (Lekavich et al., 2015).
Preload is the volume of blood filling the ventricle before it
contracts , where afterload is referred to as the pres s ure the
ventricle has to work agains t when ejecting blood out of the
ventricles generated by the pulmonary and s ys temic circulatory
s ys tems (Cas ey, 2013, p. 22). Preload is reflected by blood
volume, therefore a change in levels alters preload and s troke
volumes . Afterload increas es with a ris e in peripheral vas cular
res is tance, caus ing the ventricles to work harder than normal.
Contractility is referred to as the heart mus cle’s ability to eject
the blood out of the ventricles (Cas ey, 2013, p. 22). Contractility
is mos t often altered as a res ult of damage after a heart attack.
Contractility can als o be altered by changes in blood calcium
level, a proces s that occurs with myocardial cell injury, which
reduces cardiac output (Marín-G arcía, 2016).

• The prevalence of this dis eas e is very high in the
U nited States , and it is going to continue to ris e.
According to Reddy & Borlaug (2016), it is expected
that approximately 8 million adults in the U nited
States will have heart failure in 2030. Prognos is is
often poor and quality of life for patients is
diminis hed, caus ing s tres s and hards hip for patients
and their family members . Roughly half of the people
who develop heart failure die within five years of
diagnos is (Brias oulis , Androulakis , Chris tophides , &
Tous oulis , 2016).
• W ith s uch a wides pread dis eas e, it is vital that
healthcare providers become familiar with dis eas e
pres entation, contributing factors , and treatment
options . According to Reddy & Borlaug (2016), the
cos t of healthcare for heart failure was es timated to
be $21 billion in 2012. Cons equently, it is important
for an advanced practice nurs e frequently
encountering thes e patients to unders tand the
pathophys iology behind the dis eas e proces s to
determine the proper choice of treatment to help
further reduce cos t.

Signs and Symptoms
• According to N ichols on (2014), s igns of heart failure
include tachypnea, tachycardia, abnormal puls e,
dis placed apex beat, extra heart s ound, rais ed
jugular venous pres s ure, heart murmurs , wheez ing,
lung crepitus , weight gain and edema, pleural
effus ions , hepatomegaly, and tis s ue was ting. Many
of thes e s igns are caus ed by abnormalities of the
myocardial tis s ue as a res ult of the compens atory
mechanis ms that produce fluid retention and
vas ocons triction in order to improve cardiac output
and perfus ion.
• According to N ichols on (2014), s ymptoms of heart
failure include breathles s nes s , orthopnea,
paroxys mal nocturnal dys pnea, nocturnal cough,
s leep dis orders , fatigue, reduced exercis e tolerance,
peripheral edema, los s of appetite, bloated feeling,
confus ion, palpitations , angina, s yncope,
depres s ion and anxiety.

RAAS

SNS

W hen there is a decreas e in blood pres s ure and cardiac output,
the s ympathetic nervous s ys tem (SN S) is activated. Stimulation
of the s ympathetic nervous s ys tem generates the releas e of
noradrenaline (norepinephrine), which triggers beta-receptors
to increas e heart rate, s trength and s peed of contractions
(Cas ey, 2013, p. 22). As a res ult of increas ed heart rate, the
ventricles begin to thicken (hypertrophy) and collagen
depos ition occurs , caus ing dys function, this is called
remodeling (Anders en, Anders en, de Man, & N iels en-Kuds k,
2015). Ventricular hypertrophy has a s ignificantly negative
effect on the heart’s contractility. Mechanical s timulation to the
myocardium is the main factor of myocardial hypertrophy,
whereas myocardial fibros is may be caus ed by neurohumoral
compens atory mechanis ms s uch as cytokines and hormones
(Komamura, 2013). Overtime, this compens atory mechanis m
can become toxic to the heart cells , therefore rendering the
cells unable to res pond to the body’s attempts to compens ate.

Remodeling

W hen the heart is unable to effectively function as a pump the
renin-angiotens in-aldos terone
s ys tem (RAAS) is activated.
Decreas ed blood flow due to poor cardiac output s timulates the

According to Marín-G arcía (2016), “three major cell death
modalities , apoptos is , necros is and autophagy, occur in
cardiomyocytes , and both gradual and acute cell death are

kidneys to releas e renin, which turns angiotens inogen into
angiotens in II (Lodge & Yous ef, 2016, p. S13). Angiotens in II has
detrimental effects to cardiac tis s ue. W hen there are cons is tent
elevated levels of Aldos terone II, vas ocons triction occurs
caus ing an increas e in blood pres s ure and myocyte hypertrophy
(Lodge & Yous ef, 2016, p. S14). The s ynthes is of aldos terone is
s timulated by angiotens in II (Sous a-Pinto, Ferreira-Pinto, Santos ,
& Leite-Moreira, 2014). Aldos terone is a hormone that caus es
s odium and water retention, which increas es blood volume, and
cardiac output (Lodge & Yous ef, 2016, p. S14). Increas ed blood
volume due to aldos terone and vas ocons triction from
angiotens in II, caus es further myocyte damage and fibros is
occurs . Another hormone that retains water and caus es
vas ocons triction is arginine vas opres s in (antidiuretic hormone
[ADH]). ADH is releas ed as a res ult of atrial s tretching and a

features of the cardiac pathophys iology, including is chemia,
myocardial infarction, and progres s ive heart failure” (p. 1).
Inflammation is important to repair damaged tis s ue, but over
activation can caus e extens ive des truction. As a res ult of
prolonged inflammation, es pecially in later s tages of heart
failure, hypertrophy, fibros is , and cell death occur in cardiac
tis s ue, which is known as remodeling (Brias oulis , Androulakis ,
Chris tophides , & Tous oulis , 2016). Damaged myocardium
produces reactive oxygen s pecies (ROS) which caus es s tres s ,
inflammation, and cell death, res ulting in the releas e of proinflammatory cytokines interleukin -1 (IL-1) and TN F-α (Sous aPinto, Ferreira-Pinto, Santos , & Leite-Moreira, 2014). Thes e
molecules exacerbate heart failure by increas ing leukocyte
attraction, proliferating the inflammatory res pons e, and
increas ing endothelial des truction. Endothelial des truction

decreas e in cardiac output (Lodge & Yous ef, 2016, p. S14).
Overs tretching as a res ult of increas ed volume, therefore
increas ed preload, decreas es cardiac output. Afterload is
increas ed due to vas ocons triction and water retention, caus ing
the heart to increas e workload res ulting in an increas e in
metabolic demands . W hen the myocytes are unable to keep up
with demands , hypertrophy and remodeling occurs . This
perpetuates the cycle of heart failure.

caus es a reduced production of nitric oxide (a known
vas odilator) therefore res ulting in vas ocons triction (Brias oulis ,
Androulakis , Chris tophides , & Tous oulis , 2016).
Vas ocons triction continues to s timulate the neurohumoral and
inflammatory res pons e, therefore proliferating the cycle of
damage.

Significance of Pathophysiology

Nursing Implications

• For nurs es taking care of patients with heart
failure, it is important to cons ider all factors
when addres s ing their care. The patient and
family s hould mos t importantly be educated
patient’s heart failure. It is vital for the provider to unders tand all factors and manifes tations the patient
on the dis eas e its elf in order to improve s elfhas in order to properly identify the patient’s ability for treatment and recovery. There are s everal
management. Lifes tyle changes commonly
different types of heart failure. Thes e include left ventricular failure (s ys tolic and dias tolic heart failure)
recommended include s moking ces s ation,
and right ventricular failure.
decreas ed alcohol cons umption, and increas e
Risk Factors
in exercis e (N ichols on, 2014). As noted by
• Common caus es of heart failure are is chemic heart dis eas e, myocardial infarction, hypertens ion, and
Cas ey (2013), emphas is was placed on the
arrhythmias (N ichols on, 2014). Other caus es include cardiomyopathies , myocarditis , valve dis orders ,
importance of diet modification including low
amyloidos is , s arcoidos is , and exces s ive alcohol us e (N ichols on, 2014).
s odium and fluid intake, in addition to clos e
monitoring of daily weights (p. 23). A note
• Ris k factors for dias tolic heart failure are well es tablis hed and include hypertens ion, older age
s hould be given to care providers to addres s
(es pecially in women), kidney dis eas e, anemia, diabetes , coronary artery dis eas e, s edentary lifes tyle,
the topic of depres s ion s ince the prevalence
and obes ity (Reddy & Borlaug, 2016). Komomura (2013) points out the s ignificant finding of a high
among thos e diagnos ed with heart failure is
comorbidity rate of obes ity, diabetes , and chronic kidney dis eas e with dias tolic heart failure, therefore
high.
emphas iz ing the importance of patient education and lifes tyle modification.
•
Appropriate control of comorbidities s uch as
• The greates t ris k factors for s ys tolic heart failure are myocardial infarction and hypertens ion (Reddy &
diabetes , hypercholes terolemia and kidney
Borlaug, 2016). Hypertens ion increas es peripheral vas cular res is tance, therefore caus ing the left
dis eas e improves cardiac outcomes (N ichols on,
ventricle to work harder, dilate, and have decreas ed contractility.
2014). Proper interventions s hould be
• Right s ided heart failure is commonly as s ociated with pulmonary dis eas e when not related to left
adminis tered bas ed off of the patient’s
ventricular dys function. Chronic obs tructive pulmonary dis eas e (COPD) caus es res is tance agains t the
pres enting s igns and s ymptoms .
right ventricle when pumping blood into the pulmonary circulation, bringing about damage.
• The goal of treatment is to improve life
expectancy and quality of life. Common
Left Heart Failure versus Right Heart Failure
pharmacological s trategies include the us e of
Left heart failure is commonly called conges tive heart failure (CHF). It can be further categoriz ed by
angiotens in-converting enz yme (ACE)
s ys tolic heart failure or dias tolic heart failure bas ed off of ejection fraction. Left heart failure is es s entially
inhibitors , diuretics , and beta-adrenoceptor
the incapability of the heart to perfus e the body’s vital organs . Right heart failure is the inability of the
blockers (beta blockers ).
heart to adequately perfus e the pulmonary circulation. Right heart failure is caus ed by increas ed
res is tance of the pulmonary circulation, caus ing the right ventricle to fail. Left heart failure is correlated
• ACE inhibitors are pres cribed to patients firs t
with pulmonary edema whereas right heart failure is connected to peripheral and vis ceral edema (Cas ey,
in HFrEF due to their ability to hinder the
2013, p. 21). Mos t often, right heart failure occurs as a res ult of left s ided heart failure.
productions of angiotens in II caus ing arteriole
vas odilation (Lekavich et al., 2015). Therefore,
they reduce preload and afterload.
U nders tanding the pathophys iology allows caregivers to determine what type of heart failure the
patient has and what s igns and s ymptoms to expect. This information als o provides the caregiver with
knowledge of other dis eas es the patient is at ris k for and what illnes s es may have contributed to the

• D iuretics are recommended for all types of
heart failure for their capability of reducing
fluid retention and overload, therefore
relieving the patient’s s ymptoms of heart
failure (Reddy & Borlaug, 2016). As a res ult of
exces s fluid being excreted, preload is reduced.
• Beta blockers are typically given in addition to
ACE inhibitors due to their ability to decreas e
the heart rate and therefore prolong dias tole
and improve ventricular filling (Reddy &
Borlaug, 2016).

Systolic Heart Failure

Diastolic Heart Failure

Sys tolic heart failure is the inability of the left
ventricle to contract effectively caus ing reduced
blood circulation to the body (Cas ey, 2013, p. 21).
Often, it is referred to as heart failure with
reduced ejection fraction (HFrEF). Ejection
fraction is s imply the percentage of blood coming
out of the left ventricle with each contraction.
Diagnos is of HFrEF is an ejection fraction <40%
with a normal being >50% (Reddy & Borlaug,
2016). The dis tinguis hing factors in s ys tolic heart
failure is ventricular dilatation and markedly
depres s ed contractility (Reddy & Borlaug, 2016).
The chief outcomes of HFrEF are pulmonary

Dias tolic heart failure is referred to as heart failure
with pres erved ejection fraction (HFpEF). Dias tolic
heart failure is when a normal ejection fraction

conges tion due to increas e in atrial pres s ure and
poor circulation due to decreas ed cardiac output.

conges tion (Komamura, 2013).

occurs with impaired left ventricular relaxation.
Typically, diagnos is of HFpEF is an ejection fraction
of >50%, which is normal (Lekavich et al., 2015).
Myocardial fibros is or hypertrophy occur often as a
res ult of hypertens ion, ending in increas ed left
ventricular s tiffnes s with decreas ed filling ability
(Komamura, 2013). The left ventricle is not filling
enough in dias tole, s o to compens ate, preload is
increas ed, which in turn increas es left atrial
pres s ure and as a res ult, directly caus es pulmonary
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